4-[4-(propan-2-yl)phenyl]-3H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-6-carboxylic acid, 95.0%, 1g

(E)-N-(4-((3-Chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide (Dacomitinib Impurity), 97%, 50mg

3-(Bis(benzyloxy)phosphoryl)propanoic acid, 95.0%, 100mg

6-Bromo-7-methylpyrazolo[1,5-a]pyridine, 97.0%, 100mg

Objectif Plan PLi 2x/0.05 IOS corrigé à l'infini, pas de correction du verre de protection. Distance de travail 18,3 mm

1-(4-Methoxyphenyl)-5-methyl-1H-pyrazole-3-carboxylic acid, 1g

2,3-dimethyl-2'-(4-methylpiperazinomethyl) benzophenone, 97.0%, 1g

4-(3-Hydroxypropyl)-2,6-dimethoxyphenol, 95.0%, 250mg

Ethyl 2-(2-methyl-1H-indol-3-yl)acetate, 97%, 1g

2-((3-(4-Cyanonaphthalen-1-yl)pyridin-4-yl)thio)-N-(methylsulfonyl)acetamide 2,2,2-trifluoroacetate, 97%, 25mg

2-Chloro-N-methylpyrimidin-4-amine, 97.0%, 1g

Colonne en polypropylène SPE CHROMABOND® SiOH, 6 ml, 1000 mg, 250 pièce(s)

3-AMINOMETHYL-3-(PYRROLIDIN-1-YL)OXETANE, 95.0%, 1g